keyword
MENU ▼
Read by QxMD icon Read
search

Psilocybin

keyword
https://www.readbyqxmd.com/read/29209235/the-endless-trip-among-the-nps-users-psychopathology-and-psychopharmacology-in-the-hallucinogen-persisting-perception-disorder-a-systematic-review
#1
REVIEW
Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery, Fabrizio Schifano
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases of HPPD...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29167644/lsd-increases-primary-process-thinking-via-serotonin-2a-receptor-activation
#2
Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H Preller, Thomas Pokorny, Oliver G Bosch, Erich Seifritz, Franz X Vollenweider
Rationale: Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking - an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces primary process thinking under placebo-controlled, standardized experimental conditions and whether these effects are related to subjective experience and 5-HT2A receptor activation...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29119217/psilocybin-with-psychological-support-for-treatment-resistant-depression-six-month-follow-up
#3
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nutt
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting...
November 8, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29116367/double-blind-comparison-of-the-two-hallucinogens-psilocybin-and-dextromethorphan-similarities-and-differences-in-subjective-experiences
#4
Theresa M Carbonaro, Matthew W Johnson, Ethan Hurwitz, Roland R Griffiths
RATIONALE: Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. OBJECTIVE: This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. METHODS: Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and placebo were administered under double-blind conditions to 20 healthy participants with histories of hallucinogen use...
November 7, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29039233/the-relationships-of-classic-psychedelic-use-with-criminal-behavior-in-the-united-states-adult-population
#5
Peter S Hendricks, Michael Scott Crawford, Karen L Cropsey, Heith Copes, N Wiles Sweat, Zach Walsh, Gregory Pavela
Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these effects has not been comprehensively explored. In this study, we tested the relationships of classic psychedelic use and psilocybin use per se with criminal behavior among over 480,000 United States adult respondents pooled from the last 13 available years of the National Survey on Drug Use and Health (2002 through 2014) while controlling for numerous covariates...
October 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29030624/psilocybin-for-treatment-resistant-depression-fmri-measured-brain-mechanisms
#6
Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran, David J Nutt
Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks...
October 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29020861/psilocybin-occasioned-mystical-type-experience-in-combination-with-meditation-and-other-spiritual-practices-produces-enduring-positive-changes-in-psychological-functioning-and-in-trait-measures-of-prosocial-attitudes-and-behaviors
#7
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst
Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2) with moderate-level ("standard") support for spiritual-practice (LD-SS); (2) high-dose (20 and 30 mg/70 kg on sessions 1 and 2, respectively) with standard support (HD-SS); and (3) high-dose (20 and 30 mg/70kg on sessions 1 and 2, respectively) with high support for spiritual practice (HD-HS)...
September 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28987938/tcb-2-7r-3-bromo-2-5-dimethoxy-bicyclo-4-2-0-octa-1-3-5-trien-7-yl-methanamine-a-hallucinogenic-drug-a-selective-5-ht2a-receptor-pharmacological-tool-or-none-of-the-above
#8
REVIEW
Giuseppe Di Giovanni, Philippe De Deurwaerdère
The development of 5-HT2A receptor agonists has been considerably marginalized since the demonstration that the tryptaminergic drugs, LSD and psilocybin, or the phenylakylamine drugs, mescaline and DOI, exert their hallucinogenic properties via the stimulation of 5-HT2A receptors. Nonetheless, the ability of drugs to stimulate 5-HT2A receptors is not necessarily associated with psychedelic experience and the hallucinogenic properties are still not understood. Several studies have increased interest in stimulating 5-HT2A receptors in various CNS diseases...
October 4, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28948056/could-hallucinogens-induce-permanent-pupillary-changes-in-ab-users-a-case-report-from-new-zealand
#9
Ahmed Al-Imam
An eighteen-year-old female patient of the Caucasian ethnicity from Australasia presented with a persistently dilated pupil causing her discomfort and occasional burning sensation when she is outdoors due to oversensitivity to sunlight. However, her pupillary reaction to light (pupillary light reflex) was intact. The patient is a known user of psychedelic substances (entheogens) including LSD, NBOMe, psilocybin, and DMT. The condition affects both eyes to the same extent. Thorough medical, neurological, and radiological examinations, including an EEG and an MRI of the head and neck region, were completely normal...
2017: Case Reports in Neurological Medicine
https://www.readbyqxmd.com/read/28947181/serotonergic-hallucinogens-in-the-treatment-of-anxiety-and-depression-in-patients-suffering-from-a-life-threatening-disease-a-systematic-review
#10
REVIEW
Simon Reiche, Leo Hermle, Stefan Gutwinski, Henrik Jungaberle, Peter Gasser, Tomislav Majić
Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently, after a long hiatus period of regulatory obstacles, interest in the clinical use of these substances has resumed. The current article provides a systematic review of studies investigating psychedelics in the treatment of symptoms of existential distress in life-threatening diseases across different periods of research, highlighting how underlying concepts have developed over time...
February 2, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28947075/psychedelic-drugs-in-biomedicine
#11
REVIEW
Evan J Kyzar, Charles D Nichols, Raul R Gainetdinov, David E Nichols, Allan V Kalueff
Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials, suggesting these compounds as promising treatments for addiction, depression, anxiety, and other conditions. However, many questions regarding the mechanisms of action, safety, and efficacy of psychedelics remain...
November 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/28918722/psilocybin-assisted-therapy-for-anxiety-and-depression-implications-for-euthanasia
#12
Nigel Strauss
No abstract text is available yet for this article.
June 19, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28870224/psychoactive-substances-as-a-last-resort-a-qualitative-study-of-self-treatment-of-migraine-and-cluster-headaches
#13
Martin Andersson, Mari Persson, Anette Kjellgren
BACKGROUND: Treatment resistant cluster headache and migraine patients are exploring alternative treatments online. The aim of this study was to improve comprehension regarding the use of non-established or alternative pharmacological treatments used by sufferers of cluster headaches and migraines. METHODS: A qualitative thematic analysis of the users' own accounts presented in online forum discussions were conducted. The forum boards https://shroomery.org/ , http://bluelight...
September 5, 2017: Harm Reduction Journal
https://www.readbyqxmd.com/read/28836272/psychedelic-drugs-as-therapeutics-no-illusions-about-the-challenges
#14
Edward M Sellers, Deborah B Leiderman
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
August 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28790944/qualitative-and-quantitative-features-of-music-reported-to-support-peak-mystical-experiences-during-psychedelic-therapy-sessions
#15
Frederick S Barrett, Hollis Robbins, David Smooke, Jenine L Brown, Roland R Griffiths
Psilocybin is a classic (serotonergic) hallucinogen ("psychedelic" drug) that may occasion mystical experiences (characterized by a profound feeling of oneness or unity) during acute effects. Such experiences may have therapeutic value. Research and clinical applications of psychedelics usually include music listening during acute drug effects, based on the expectation that music will provide psychological support during the acute effects of psychedelic drugs, and may even facilitate the occurrence of mystical experiences...
2017: Frontiers in Psychology
https://www.readbyqxmd.com/read/28768346/-psychotherapy-with-adjuvant-use-of-serotonergic-psychoactive-substances-possibilities-and-challenges
#16
Tomislav Majić, Henrik Jungaberle, Timo T Schmidt, Andrea Zeuch, Leo Hermle, Jürgen Gallinat
Background Recently, scientific interest in the therapeutic potential of serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) within the framework of psychotherapy has resumed. The present article provides an overview on the current evidence on substance-assisted psychotherapy with these substances. Method A selective search was carried out in the PubMed and Cochrane Library including studies investigating the clinical use of serotonergic psychoactive substances since 2000...
July 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28763571/enzymatic-synthesis-of-psilocybin
#17
Janis Fricke, Felix Blei, Dirk Hoffmeister
Psilocybin is the psychotropic tryptamine-derived natural product of Psilocybe carpophores, the so-called "magic mushrooms". Although its structure has been known for 60 years, the enzymatic basis of its biosynthesis has remained obscure. We characterized four psilocybin biosynthesis enzymes, namely i) PsiD, which represents a new class of fungal l-tryptophan decarboxylases, ii) PsiK, which catalyzes the phosphotransfer step, iii) the methyltransferase PsiM, catalyzing iterative N-methyl transfer as the terminal biosynthetic step, and iv) PsiH, a monooxygenase...
August 1, 2017: Angewandte Chemie
https://www.readbyqxmd.com/read/28711736/two-dose-investigation-of-the-5-ht-agonist-psilocybin-on-relative-and-global-cerebral-blood-flow
#18
Candace R Lewis, Katrin H Preller, Rainer Kraehenmann, Lars Michels, Philipp Staempfli, Franz X Vollenweider
Psilocybin, the active compound in psychedelic mushrooms, is an agonist of various serotonin receptors. Seminal psilocybin positron emission tomography (PET) research suggested regional increases in glucose metabolism in frontal cortex (hyperfrontality). However, a recent arterial spin labeling (ASL) study suggests psilocybin may lead to hypo-perfusion in various brain regions. In this placebo-controlled, double-blind study we used pseudo-continuous ASL (pCASL) to measure perfusion changes, with and without adjustment for global brain perfusion, after two doses of oral psilocybin (low dose: 0...
July 12, 2017: NeuroImage
https://www.readbyqxmd.com/read/28678583/lsd-treatment-in-scandinavia-emphasizing-indications-and-short-term-treatment-outcomes-of-151-patients-in-denmark
#19
Jens Knud Larsen
BACKGROUND: New research has suggested the clinical use of lysergic acid diethylamide (LSD) and psilocybin in selected patient populations. However, concerns about the clinical use of LSD were advanced in a large Danish follow-up study that assessed 151 LSD-treated psychiatric patients approximately 25 years after their treatment in the 1960s. AIMS: The purpose of the present study was to give a retrospective account of the short-term outcome of LSD treatment in these 151 Danish psychiatric patients...
October 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/28677096/hallucinogens-and-serotonin-5-ht2a-receptor-mediated-signaling-pathways
#20
Juan F López-Giménez, Javier González-Maeso
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include naturally occurring chemicals such as mescaline and psilocybin, as well as synthetic compounds, such as lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion, and cognition. The discovery of the hallucinogenic effects of LSD and the observations that LSD and the endogenous ligand serotonin share chemical and pharmacological profiles led to the suggestion that biogenic amines like serotonin were involved in the psychosis of mental disorders such as schizophrenia...
July 5, 2017: Current Topics in Behavioral Neurosciences
keyword
keyword
20841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"